Domperidone, at a dosage of 20 mg t.d.s before meals, in a double-blind, crossover, placebo-controlled trial reduced the level of the symptoms of dyspepsia by 76% compared to a 16% reduction with placebo. This difference was statistically significant (p less than 0.001). Thirteen of the fourteen patients in the study preferred domperidone to placebo. Four patients in the active treatment period and one in the placebo complained of mild side-effects.

Download full-text PDF

Source
http://dx.doi.org/10.1177/030006057900700208DOI Listing

Publication Analysis

Top Keywords

domperidone treatment
4
treatment dyspepsia
4
dyspepsia double-blind
4
double-blind placebo-controlled
4
placebo-controlled study
4
study domperidone
4
domperidone dosage
4
dosage tds
4
tds meals
4
meals double-blind
4

Similar Publications

Article Synopsis
  • A study examined the effectiveness and safety of Aurantii Fructus Immaturus flavonoid (AFIF) tablets compared to domperidone for treating functional dyspepsia (FD).
  • After 4 weeks of treatment, both AFIF and domperidone showed similar rates of symptom relief, but AFIF had a significantly higher rate of symptom disappearance 4 weeks after stopping treatment.
  • The AFIF group also experienced fewer adverse events, suggesting a better safety profile compared to domperidone.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess how Weichang'an pill (WCAP) affects functional dyspepsia (FD) in rats, focusing on brain-gut peptides and gut microbiota as potential treatment mechanisms.
  • Researchers created an FD rat model and divided the rats into different treatment groups, including those receiving WCAP and a control for comparison, then measured gastrointestinal motility and gut microbiota composition.
  • Results showed that WCAP improved FD symptoms by enhancing gastric emptying, regulating brain-gut peptide levels, and restoring gut microbiota balance, suggesting it could be an effective treatment for FD.
View Article and Find Full Text PDF

Brain drug delivery from the nasal olfactory region is enhanced using lauroylcholine chloride: An estimation using in vivo PET imaging.

Nucl Med Biol

December 2024

Molecular Imaging Laboratory, Division of Preeminent Bioimaging Research, Institute of Photonics Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu 431-3192, Japan. Electronic address:

Introduction: Intranasal (IN) administration, often referred to as nose-to-brain (N2B) drug delivery, is an attractive approach for delivering drugs to the central nervous system. However, the efficacy of this method is limited because of the small size of the nasal olfactory region, which limits the drug dosage. Using permeation enhancers could improve drug delivery from this region to the brain, though their effects are not fully understood.

View Article and Find Full Text PDF

Proteomic Insights into the Effects of Jianweixiaoshi Tablets on Functional Dyspepsia with Spleen Deficiency in Rats.

Drug Des Devel Ther

November 2024

State Key Laboratory for the Modernization of Classical and Famous Prescriptions of Chinese Medicine, Nanchang, 330096, People's Republic of China.

Background: Jianweixiaoshi tablets (JWXS) is widely used in traditional Chinese medicine for treating functional dyspepsia with spleen deficiency (SD-FD) in China. However, the molecular mechanisms underlying the therapeutic effects of JWXS remain incompletely understood.

Methods: Functional dyspepsia was induced in rats with spleen deficiency by iodoacetamide in combination with the modified multiple platform method.

View Article and Find Full Text PDF

The present study was designed to measure the potential antiemetic properties of nerolidol (NDL) via in vivo and in silico studies. To induce emesis copper sulfate pentahydrate (CuSO.5HO) was administered at a dose of 50 mg/kg (orally) to 2-day-old chicks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!